tiprankstipranks
Advertisement
Advertisement

OSTX Stock Latest News

OS Therapies price target lowered to $13 from $14 at Lake Street
The FlyOS Therapies price target lowered to $13 from $14 at Lake Street
28d ago
OSTX
OS Therapies Delays Quarterly SEC Filing
PremiumCompany Announcements
OS Therapies Delays Quarterly SEC Filing
1M ago
OSTX
OS Therapies Gains EMA Rolling Review for OST-HER2
PremiumCompany Announcements
OS Therapies Gains EMA Rolling Review for OST-HER2
2M ago
8K
OSTX
OSTX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OSTX Earnings this Week: How Will it Perform?
2M ago
OSTX
OS Therapies bolsters funding to advance OST-HER2 program
PremiumCompany Announcements
OS Therapies bolsters funding to advance OST-HER2 program
2M ago
8K
OSTX
Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
PremiumRatingsRegulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
3M ago
OSTX
OS Therapies price target lowered to $14 from $17 at Lake Street
Premium
The Fly
OS Therapies price target lowered to $14 from $17 at Lake Street
3M ago
OSTX
OS Therapies Files Prospectus Supplement for Share Resale
Premium
Company Announcements
OS Therapies Files Prospectus Supplement for Share Resale
3M ago
8K
OSTX
OS Therapies Raises $2 Million via Convertible Notes
PremiumCompany Announcements
OS Therapies Raises $2 Million via Convertible Notes
3M ago
8K
OSTX
OS Therapies Extends Warrant Inducement Offering Period
PremiumCompany Announcements
OS Therapies Extends Warrant Inducement Offering Period
4M ago
8K
OSTX
OS Therapies Raises Capital Through Warrant Inducement Agreements
PremiumCompany Announcements
OS Therapies Raises Capital Through Warrant Inducement Agreements
5M ago
8K
OSTX
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
PremiumRatings
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
6M ago
OSTX
OS Therapies price target lowered to $17 from $18 at Lake Street
PremiumThe FlyOS Therapies price target lowered to $17 from $18 at Lake Street
7M ago
OSTX
OS Therapies Reports Increased Losses Amid Rising R&D Costs
Premium
Company Announcements
OS Therapies Reports Increased Losses Amid Rising R&D Costs
7M ago
OSTX
OSTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
OSTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7M ago
OSTX
OS Therapies Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
OS Therapies Approves Key Proposals at Annual Meeting
8M ago
8K
OSTX
OS Therapies Releases Investor Presentation for Stakeholders
PremiumCompany Announcements
OS Therapies Releases Investor Presentation for Stakeholders
8M ago
8K
OSTX
Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
PremiumRatings
Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
8M ago
OSTX
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
PremiumRatings
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
9M ago
OSTX
OS Therapies Files Prospectus for Stock Resale
PremiumCompany AnnouncementsOS Therapies Files Prospectus for Stock Resale
9M ago
8K
OSTX
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
Premium
Ratings
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
9M ago
OSTX
OS Therapies Raises $3.7M for OST-HER2 Launch
Premium
Company Announcements
OS Therapies Raises $3.7M for OST-HER2 Launch
10M ago
8K
OSTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >